RITONAVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H48N6O5S2
Molecular Weight	720.9478
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@@]([H])(C(=N[C@@]([H])(Cc1ccccc1)C[C@@]([H])([C@]([H])(Cc2ccccc2)N=C(O)OCc3cncs3)O)O)N=C(N(C)Cc4csc(C(C)C)n4)O

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H48N6O5S2
Molecular Weight	720.9478
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf
Curator's Comment:: http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 2B6 19 Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159797	Inhibitor 7701		2.20000000000000018 µM [IC50]
Cytochrome P450 3A 21 Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952482	Inhibitor 7701		0.140000000000000013 µM [IC50]
Human immunodeficiency virus type 1 protease 33 Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17627597	Inhibitor 7701	HIV-1 infection	0.0100000000000000002 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 140 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf	Primary	Human immunodeficiency virus type 1 protease	Approved 7997	NORVIR Approved Use KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14) Launch Date 825638400000

C_max

Value	Dose	Co-administered	Analyte	Population
11.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
129 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years Health Status: healthy Age Group: 29 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Death fetal... AEs leading to discontinuation/dose reduction: Death fetal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years Health Status: healthy Age Group: 29 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Other AEs: Gastrointestinal disorder NOS, Lipids abnormal... Other AEs: Gastrointestinal disorder NOS Lipids abnormal Insulin resistance Lipoatrophy Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

AEs

AE	Significance	Dose	Population
Death fetal	1 patient Disc. AE	200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years Health Status: healthy Age Group: 29 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Hypertension	grade 2, 1 patient Disc. AE	50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years Health Status: healthy Age Group: 29 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Gastrointestinal disorder NOS		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Insulin resistance		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipids abnormal		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipoatrophy		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1470	inducer 343 inhibitor 1318	inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 175 P-gp 1089 CYP2C19 1215 CYP2E1 761 CYP1A2 1268	CYP3A 154 CYP2D 1 CYP3A5 346	CYP3A 102 CYP1A2 618 CYP2C19 260 CYP2B6 486 UGT 24 P-gp 225

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2E1 841	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2	yes [IC50 17.3 uM]	yes (co-administration study) Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2
CYP2C19 1277	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 23.5 uM]
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 6.2 uM]
CYP1A2 1406	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	yes
CYP2B6 845	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19	yes
CYP2C19 1277	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19	yes
CYP2C9 1362	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	yes
CYP3A 244	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	yes
CYP3A 244	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	yes
P-gp 1255	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51	yes
P-gp 1255	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51	yes
UGT 49	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19	yes

Drug as victim

Target	Modality	Activity
CYP3A 154	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	major
CYP3A4 1470	substrate 2752 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.05 uM]
CYP3A5 346	substrate 2752 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.21 uM]
CYP2D 1	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.sciencedirect.com/science/article/pii/S0140673605179501 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45409	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45409
MolPort	MolPort-000-883-877	https://www.molport.com/shop/molecule-link/MolPort-000-883-877
ZINC	ZINC000003944422	http://zinc15.docking.org/substances/ZINC000003944422

PubMed

Title	Date	PubMed
Saquinavir soft gelatin capsule: a comparative safety review.	2001	11347724
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.	2001	11345223
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.	2001 Apr	11312622
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001 Apr	11306154
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.	2001 Apr 1	11317084
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.	2001 Apr 13	11371681
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.	2001 Apr 15	11401294
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.	2001 Apr 15	11391173
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.	2001 Apr 15	11391161
[An option even for patients with multiple pretreatment].	2001 Apr 2	11373796
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].	2001 Apr 2	11373793
Antiviral drugs: current state of the art.	2001 Aug	11418355
Pharmacology and clinical experience with saquinavir.	2001 Feb	11336588
Use of HIV protease inhibitors as pharmacoenhancers.	2001 Feb	11279888
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.	2001 Feb	11244316
[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].	2001 Feb	11240420
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.	2001 Feb	11236109
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.	2001 Feb	11206045
Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.	2001 Feb 10	11177411
Ritonavir-induced carbamazepine toxicity.	2001 Jan	11197575
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.	2001 Jan 20	11177388
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.	2001 Jan 26	11216928
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.	2001 Jan 26	11216926
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.	2001 Jan 5	11192874
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.	2001 Jan-Feb	11213928
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.	2001 Jun	11422019
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.	2001 Jun 1	11404537
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.	2001 Jun 1	11404533
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.	2001 Jun 1	11343221
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.	2001 Jun 15	11417878
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.	2001 Jun 15	11416725
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.	2001 Jun 15	11396919
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.	2001 Mar	11396754
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.	2001 Mar	11239054
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.	2001 Mar 1	11242194
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.	2001 Mar 1	11229864
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.	2001 Mar 26	11309224
[HIV: a guide on management of seropositive patients].	2001 Mar 3	11268903
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.	2001 Mar 30	11317012
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.	2001 Mar 9	11242145
Lopinavir/ritonavir.	2001 Mar-Apr	11296724
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.	2001 May	11322888
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.	2001 May	11297905
A potential role for interleukin-7 in T-cell homeostasis.	2001 May 15	11342421
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.	2001 May 25	11399999
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.	2001 May 25	11399984
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.	2001 May 25	11399983
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.	2001 May 4	11399957
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.	2001 May 5	11393736

Patents

Sample Use Guides

In Vivo Use Guide

600 mg twice-day with meals.

Route of Administration: Oral

In Vitro Use Guide

Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:55:55 UTC 2021` Edited by `admin` on `Fri Jun 25 20:55:55 UTC 2021`
Record UNII	O3J8G9O825
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RITONAVIR

Official Name

English

NORVIR

Brand Name

English

RITONAVIR [VANDF]

Common Name

English

RITONAVIR [MI]

Common Name

English

RITONAVIR [WHO-DD]

Common Name

English

VIRITON

Brand Name

English

EMPETUS

Brand Name

English

RITONAVIR [INN]

Common Name

English

RITONAVIR [USP]

Common Name

English

ABBOTT-84538

Code

English

VIEKIRAX COMPONENT RITONAVIR

Brand Name

English

RITOVIR

Brand Name

English

KALETRA COMPONENT RITONAVIR

Common Name

English

RITONAVIR [HSDB]

Common Name

English

RITONAVIR [USP-RS]

Common Name

English

NSC-693184

Code

English

ABT-538

Code

English

RITONAVIR COMPONENT OF VIEKIRAX

Brand Name

English

RTV

Common Name

English

RITONAVIR [EMA EPAR]

Common Name

English

RITONAVIR [JAN]

Common Name

English

RITONAVIR COMPONENT OF KALETRA

Common Name

English

RITONAVIR [ORANGE BOOK]

Common Name

English

RITONAVIRUM [WHO-IP LATIN]

Common Name

English

A-84538

Code

English

RITOMUNE

Brand Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE

Common Name

English

2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-

Systematic Name

English

RITONAVIR [MART.]

Common Name

English

2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-

Common Name

English

RITONAVIR [USP MONOGRAPH]

Common Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]

Common Name

English

RITONAVIR [WHO-IP]

Common Name

English

VIEKIRAX

Brand Name

English

5-THIAZOLYLMETHYL ((.ALPHA.S)-.ALPHA.-((1S,3S)-1-HYDROXY-3-((2S)-2-(3-((2-ISOPROPYL-4-THIAZOLYL)METHYL)-3-METHYLUREIDO)-3-METHYLBUTYRAMIDO)-4-PHENYLBUTYL)PHENETHYL)CARBAMATE

Common Name

English

RITONAVIR [USAN]

Common Name

English

Classification Tree Code System Code

LIVERTOX

853